Table 1 Basic characteristics of all patients
From: Novel model based on ultrasound predict axillary lymph node metastasis in breast cancer
Total | Train | Test | P-value | |
|---|---|---|---|---|
Lymph metastasis | ||||
No | 154 (56.4%) | 105 (55.0%) | 49 (59.8%) | 0.51 |
Yes | 119 (43.6%) | 86 (45.0%) | 33 (40.2%) | |
Menopausal | ||||
Premenopausal | 131 (48.0%) | 88 (46.1%) | 43 (52.4%) | 0.36 |
Postmenopausal | 142 (52.0%) | 103 (53.9%) | 39 (47.6%) | |
Location | ||||
Upper-out | 74 (27.1%) | 54 (28.3%) | 20 (24.4%) | 0.97 |
Lower-out | 34 (12.5%) | 24 (12.6%) | 10 (12.2%) | |
Upper inner | 69 (25.3%) | 47 (24.6%) | 22 (26.8%) | |
Lower inner | 76 (27.8%) | 52 (27.2%) | 24 (29.3%) | |
Center | 20 (7.3%) | 14 (7.3%) | 6 (7.3%) | |
Histological grade | ||||
I | 54 (19.8%) | 35 (18.3%) | 19 (23.2%) | 0.4 |
II | 81 (29.7%) | 61 (31.9%) | 20 (24.4%) | |
III | 138 (50.5%) | 95 (49.7%) | 43 (52.4%) | |
Histological type | ||||
Ductal | 245 (89.7%) | 177 (92.7%) | 68 (82.9%) | 0.028 |
Lobular | 15 (5.5%) | 9 (4.7%) | 6 (7.3%) | |
Other | 13 (4.8%) | 5 (2.6%) | 8 (9.8%) | |
ER | ||||
1+ | 39 (14.3%) | 29 (15.2%) | 10 (12.2%) | 0.78 |
2+ | 36 (13.2%) | 27 (14.1%) | 9 (11.0%) | |
3+ | 100 (36.6%) | 67 (35.1%) | 33 (40.2%) | |
Negative | 98 (35.9%) | 68 (35.6%) | 30 (36.6%) | |
PR | ||||
1+ | 37 (13.6%) | 27 (14.1%) | 10 (12.2%) | 0.88 |
2+ | 46 (16.8%) | 31 (16.2%) | 15 (18.3%) | |
3+ | 64 (23.4%) | 43 (22.5%) | 21 (25.6%) | |
Negative | 126 (46.2%) | 90 (47.1%) | 36 (43.9%) | |
Her2 | ||||
Negative | 178 (65.2%) | 124 (64.9%) | 54 (65.9%) | 1 |
Positive | 95 (34.8%) | 67 (35.1%) | 28 (34.1%) | |
Ki67 | ||||
Smaller14 | 50 (18.3%) | 32 (16.8%) | 18 (22.0%) | 0.31 |
Bigger14 | 223 (81.7%) | 159 (83.2%) | 64 (78.0%) | |
P53 | ||||
Negative | 97 (35.5%) | 69 (36.1%) | 28 (34.1%) | 0.78 |
Positive | 176 (64.5%) | 122 (63.9%) | 54 (65.9%) | |
VEGF-C | ||||
Negative | 70 (25.6%) | 50 (26.2%) | 20 (24.4%) | 0.88 |
Positive | 203 (74.4%) | 141 (73.8%) | 62 (75.6%) | |
Regular shape | ||||
Yes | 142 (52.0%) | 99 (51.8%) | 43 (52.4%) | 1 |
No | 131 (48.0%) | 92 (48.2%) | 39 (47.6%) | |
Boundary | ||||
Clearly | 133 (48.7%) | 87 (45.5%) | 46 (56.1%) | 0.12 |
Obscure | 140 (51.3%) | 104 (54.5%) | 36 (43.9%) | |
Echo | ||||
Homogeneous | 132 (48.4%) | 85 (44.5%) | 47 (57.3%) | 0.064 |
Heterogeneous | 141 (51.6%) | 106 (55.5%) | 35 (42.7%) | |
Calcification | ||||
No | 135 (49.5%) | 95 (49.7%) | 40 (48.8%) | 0.9 |
Yes | 138 (50.5%) | 96 (50.3%) | 42 (51.2%) | |
Age(years) | 49.7 ± 8.7 | 49.9 ± 8.9 | 49.3 ± 8.3 | 0.61 |
Diameter(cm) | 14.5 ± 5.2 | 14.6 ± 5.2 | 14.1 ± 5.4 | 0.31 |
Tumor peak systolic flow velocity(PS) | 38.1 ± 6.1 | 37.6 ± 6.0 | 39.0 ± 6.1 | 0.089 |
Tumor end diastolic flow velocity(EDF) | 10.1 ± 2.2 | 10.2 ± 2.2 | 10.0 ± 2.1 | 0.53 |
Tumor systolic velocity to end of diastolic velocity ratio(SD) | 4.0 ± 1.1 | 3.9 ± 1.1 | 4.1 ± 1.2 | 0.15 |
Tumor resistance index(RI) | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.28 |
Tumor pulsatility index(PI) | 1.8 ± 0.3 | 1.8 ± 0.3 | 1.8 ± 0.3 | 0.31 |
lymphatic transverse | 5.9 ± 1.3 | 6.0 ± 1.2 | 5.8 ± 1.3 | 0.24 |
lymphatic longitudinal | 11.6 ± 2.1 | 11.8 ± 2.1 | 11.3 ± 2.0 | 0.068 |
cortex area hilum ratio(CH) | 1.9 ± 0.3 | 1.9 ± 0.3 | 1.9 ± 0.3 | 0.49 |
Lymph peak systolic flow velocity(PS) | 17.4 ± 6.2 | 17.4 ± 6.2 | 17.3 ± 6.3 | 0.97 |
Lymph end diastolic flow velocity(EDF) | 8.0 ± 2.1 | 7.9 ± 2.1 | 8.1 ± 2.2 | 0.33 |
Lymph systolic velocity to end of diastolic velocity ratio(SD) | 3.2 ± 1.7 | 3.2 ± 1.8 | 3.2 ± 1.7 | 0.43 |
Lymph resistance index(RI) | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.97 |
Lymph pulsatility index(PI) | 1.7 ± 0.3 | 1.7 ± 0.3 | 1.7 ± 0.3 | 0.31 |